DWTX Relative Valuation
DWTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, DWTX is overvalued; if below, it's undervalued.
Historical Valuation
Dogwood Therapeutics Inc (DWTX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.16. The fair price of Dogwood Therapeutics Inc (DWTX) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：3.97
Fair
-1.52
PE
1Y
3Y
5Y
0.00
EV/EBITDA
Dogwood Therapeutics Inc. (DWTX) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
-6.93
EV/EBIT
Dogwood Therapeutics Inc. (DWTX) has a current EV/EBIT of -6.93. The 5-year average EV/EBIT is -1.82. The thresholds are as follows: Strongly Undervalued below -6.05, Undervalued between -6.05 and -3.94, Fairly Valued between 0.29 and -3.94, Overvalued between 0.29 and 2.41, and Strongly Overvalued above 2.41. The current Forward EV/EBIT of -6.93 falls within the Strongly Undervalued range.
0.00
PS
Dogwood Therapeutics Inc. (DWTX) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.
0.00
P/OCF
Dogwood Therapeutics Inc. (DWTX) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.
0.00
P/FCF
Dogwood Therapeutics Inc. (DWTX) has a current P/FCF of 0.00. The 5-year average P/FCF is -0.27. The thresholds are as follows: Strongly Undervalued below -1.28, Undervalued between -1.28 and -0.77, Fairly Valued between 0.24 and -0.77, Overvalued between 0.24 and 0.75, and Strongly Overvalued above 0.75. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Dogwood Therapeutics Inc (DWTX) has a current Price-to-Book (P/B) ratio of -0.29. Compared to its 3-year average P/B ratio of 2.11 , the current P/B ratio is approximately -113.92% higher. Relative to its 5-year average P/B ratio of 2.35, the current P/B ratio is about -112.50% higher. Dogwood Therapeutics Inc (DWTX) has a Forward Free Cash Flow (FCF) yield of approximately -14.37%. Compared to its 3-year average FCF yield of -87.32%, the current FCF yield is approximately -83.54% lower. Relative to its 5-year average FCF yield of -76.15% , the current FCF yield is about -81.13% lower.
-0.29
P/B
Median3y
2.11
Median5y
2.35
-14.37
FCF Yield
Median3y
-87.32
Median5y
-76.15
Competitors Valuation Multiple
The average P/S ratio for DWTX's competitors is 235.65, providing a benchmark for relative valuation. Dogwood Therapeutics Inc Corp (DWTX) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of DWTX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of DWTX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is Dogwood Therapeutics Inc (DWTX) currently overvalued or undervalued?
Dogwood Therapeutics Inc (DWTX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.16. The fair price of Dogwood Therapeutics Inc (DWTX) is between to according to relative valuation methord.
What is Dogwood Therapeutics Inc (DWTX) fair value?
DWTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Dogwood Therapeutics Inc (DWTX) is between to according to relative valuation methord.
How does DWTX's valuation metrics compare to the industry average?
The average P/S ratio for DWTX's competitors is 235.65, providing a benchmark for relative valuation. Dogwood Therapeutics Inc Corp (DWTX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Dogwood Therapeutics Inc (DWTX) as of Jan 07 2026?
As of Jan 07 2026, Dogwood Therapeutics Inc (DWTX) has a P/B ratio of -0.29. This indicates that the market values DWTX at -0.29 times its book value.
What is the current FCF Yield for Dogwood Therapeutics Inc (DWTX) as of Jan 07 2026?
As of Jan 07 2026, Dogwood Therapeutics Inc (DWTX) has a FCF Yield of -14.37%. This means that for every dollar of Dogwood Therapeutics Inc’s market capitalization, the company generates -14.37 cents in free cash flow.
What is the current Forward P/E ratio for Dogwood Therapeutics Inc (DWTX) as of Jan 07 2026?
As of Jan 07 2026, Dogwood Therapeutics Inc (DWTX) has a Forward P/E ratio of -1.52. This means the market is willing to pay $-1.52 for every dollar of Dogwood Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Dogwood Therapeutics Inc (DWTX) as of Jan 07 2026?
As of Jan 07 2026, Dogwood Therapeutics Inc (DWTX) has a Forward P/S ratio of 0.00. This means the market is valuing DWTX at $0.00 for every dollar of expected revenue over the next 12 months.